Company news
Mink Therapeutics, Inc. (NASDAQ:INKT) news
Every Mink Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Ac...
August 13, 2026
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
June 3, 2026
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
May 28, 2026
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology C...
May 20, 2026
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
May 15, 2026
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critic...
May 14, 2026
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
May 8, 2026
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
May 4, 2026
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
April 17, 2026
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Can...
April 3, 2026
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
April 2, 2026
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
April 1, 2026
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
March 31, 2026
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy...
March 17, 2026
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
March 10, 2026
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
March 4, 2026
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis ...
February 3, 2026
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate P...
January 8, 2026
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
November 20, 2025
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, an...
November 14, 2025
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors...
November 7, 2025
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform ...
November 5, 2025
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC...
October 30, 2025
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
September 29, 2025
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
September 25, 2025
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
September 18, 2025
Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK ...
August 26, 2025
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
August 14, 2025
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
July 31, 2025
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Bar...
July 15, 2025
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
July 11, 2025
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 10, 2025
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
June 2, 2025
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
May 15, 2025
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
March 18, 2025
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
March 4, 2025
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
February 24, 2025
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
February 20, 2025
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
February 12, 2025
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT...
January 23, 2025
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
December 18, 2024
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
November 14, 2024
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
November 11, 2024
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
October 31, 2024
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
October 8, 2024
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
October 4, 2024
MiNK Reports Second Quarter 2024 Results and Business Update
August 13, 2024
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
August 1, 2024
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
July 31, 2024
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
May 22, 2024